Found 49 Solid Tumors trials
A listing of Solid Tumors medical research trials actively recruiting patient volunteers. Search for closest city to find more detailed information on a research study in your area.
UPCC 11917: A Dose-Finding Phase 1 Study of TAS-120 in Patients With Advanced Solid Tumors With or Without Fibroblast Growth Factor/Receptor (FGF/FGFR)-Related Abnormalities followed by a Phase 2 Study in Patients with Advanced Solid Tumors with FGF/FGFR-Related Abnormalities
Request for collaborative review: WIRB serving as IRB of record.
UPCC 04122 A Phase 1 Open-Label Multicenter Study of INCB123667 as Monotherapy in Participants With Selected Advanced Solid Tumors
Please refer to Protocol Section 3 (Objectives and Endpoints). Please refer to Protocol Section 3 (Objectives and Endpoints). Please refer to Protocol Section 3 (Objectives and Endpoints).
UPCC 06918:A Phase 1a/1b Study Exploring the Safety and Tolerability of INCB081776 in Participants With Advanced Solid Tumors
We are requesting to rely on WIRB as IRB of record for this study. This Study has 2 parts. The purpose of the Part 1 is to try to find the best dose of INCB081776 alone for patients who have advanced cancer. The purpose of Part 2 is to find …
UPCC 12922: An Early Phase Study to Evaluate the Safety Tolerability Pharmacokinetics and Preliminary Antitumor Activity of PEEL-224 in Patients with Advanced Solid Tumors
Please refer to Protocol Section 2 (Study Objectives and Endpoints). Please refer to Protocol Section 2 (Study Objectives and Endpoints). Please refer to Protocol Section 2 (Study Objectives and Endpoints).
UPCC 32922: A Phase 1 First-in-Human Study of IK-930 an Oral TEAD Inhibitor Targeting the Hippo Pathway in Subjects With Advanced Solid Tumors
Please refer to Protocol, Section 1.1.3. (Study Objectives and Endpoints) Please refer to Protocol, Section 3. (Objectives and Endpoints) Please refer to Protocol, Section 3. (Objectives and Endpoints)
UPCC 03920: A Phase 1/1b Open-label Dose-escalation and Dose-expansion Study of TPST-1120 as a Single Agent or in Combination with Systemic Anti-Cancer Therapies in Subjects with Advanced Solid Tumors
This is a Phase 1 study that will evaluate the effectiveness of TPST-1120. Subjects may receive TPST-1120 alone or in combination with nivolumab. Subjects eligible to participate are those with advanced solid tumors.
Study with Safety Run-in to Evaluate the Safety Tolerability and Preliminary Efficacy of FF-10832 Monotherapy or in Combination with Pembrolizumab in Patients with Advanced Solid Tumors
The purpose of this study are to determine the maximum dose of FF-10832 that can be tolerated when taken in combination with pembrolizumab and to determine whether FF10832 taken by itself or in combination with pembrolizumab has anti-tumor activity.
UPCC 35922: Phase 1/2 Safety and Efficacy Study of NUV-868 as Monotherapy and in Combination With Olaparib or Enzalutamide in Adult Patients With Advanced Solid Tumors
Please see Protocol NUV-868-01, Section 3 (Objectives and Endpoints) Please see Protocol NUV-868-01, Section 3 (Objectives and Endpoints) Please see Protocol NUV-868-01, Section 3 (Objectives and Endpoints)
Please choose between Voice or SMS based delivery of verification code
or